HRS-7058 + SHR-1826

HRS-7058 + SHR-1826 is an investigational combination therapy under clinical development for the treatment of advanced solid tumors, including non-small cell lung cancer. HRS-7058 is a next-generation small molecule inhibitor targeting KRAS G12C mutations, designed to block oncogenic signaling in tumor cells with this mutation[4][5][6][8]. SHR-1826 is an antibody-drug conjugate (ADC) targeting c-Met, a receptor tyrosine kinase implicated in tumor growth and metastasis[4][7]. The combination aims to leverage the direct inhibition of mutant KRAS-driven pathways by HRS-7058 and targeted cytotoxic delivery via c-Met by SHR-1826. Both agents are being developed by Jiangsu Hengrui Medicine (Hengrui), with clinical studies evaluating their safety, tolerability, pharmacokinetics, and efficacy in patients with advanced malignancies[1][2][3].